The room-temperature collagen pad, approved for hemostasis and sealing, features an extended shelf life of three years. It involves the interaction of two components that can create rapid and lasting hemostasis by sealing off the bleeding surface.

Preclinical studies have shown that patch resorption and replacement with host tissue takes place within about six to eight weeks, according to Baxter.

Steve Wallace, president of Advanced Surgery at Baxter, explained in a promotional video that Baxter created and tested over 400 prototypes before it launched the latest version of Hemopatch. The patch was originally launched in 2013 as a hemostatic patch and received its sealing indication in 2016.